Meeting
2013 ASCO Annual Meeting
Use of intravaginal 17-β estradiol to improve sexual function and menopausal symptoms in postmenopausal women with breast cancer on aromatase inhibitors.
Authors
Shari Beth Goldfarb
Memorial Sloan-Kettering Cancer Center, New York, NY
Shari Beth Goldfarb , Maura N. Dickler , Ann M. Dnistrian , Sujata Patil , Lara Dunn , Kaity Chang , Alyssa Peri Berkowitz , Noah Tucker , Jeanne Carter , Richard R. Barakat , Clifford Hudis , Mercedes Castiel
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Patient and Survivor Care
Track
Patient and Survivor Care
Sub Track
Survivorship
Citation
J Clin Oncol 31, 2013 (suppl; abstr 9610)
DOI
10.1200/jco.2013.31.15_suppl.9610
Abstract #
9610
Poster Bd #
36F
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
Associations between preexisting nociplastic pain and early discontinuation of aromatase inhibitor therapy in breast cancer.
First Author: Elizabeth Joyce
Poster
2014 Breast Cancer Symposium
Efficacy of subcutaneous testosterone on menopausal symptoms in breast cancer survivors.
First Author: Rebecca L. Glaser
Poster
2021 ASCO Annual Meeting
Bone safety profile of steroidal aromatase inhibitor in comparison to non-steroidal aromatase inhibitors in postmenopausal women with breast cancer: A network meta-analysis.
First Author: Shanshan Chen
Poster
2018 ASCO Annual Meeting
Association of a low-expression SLCO1B1 polymorphism with estrogen concentrations before and during aromatase inhibitor treatment for breast cancer.
First Author: Jacqueline M Dempsey